1
|
Bazarbashi S, El Zawahry HM, Owaidah T, AlBader MA, Warsi A, Marashi M, Dawoud E, Jaafar H, Sholkamy SM, Haddad F, Cohen AT. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts. J Blood Med 2024; 15:171-189. [PMID: 38686358 PMCID: PMC11057512 DOI: 10.2147/jbm.s411520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Accepted: 03/01/2024] [Indexed: 05/02/2024] Open
Abstract
Venous thromboembolism is a leading cause of morbidity and mortality in patients with active cancer who require anticoagulation treatment. Choice of anticoagulant is based on careful balancing of the risks and benefits of available classes of treatment: vitamin K antagonists, low-molecular-weight heparin (LMWH), and direct oral anticoagulants (DOACs). Results from randomized controlled trials have shown the consistent efficacy of DOACs versus LMWH in the treatment of cancer-associated venous thromboembolism (VTE). However, increased major gastrointestinal bleeding was observed for edoxaban and rivaroxaban, but not apixaban, compared with LMWH dalteparin. Most guidelines recommend DOACs for the treatment of cancer-associated VTE in patients without gastrointestinal or genitourinary cancer, and with considerations for renal impairment and drug-drug interactions. These updates represent a major paradigm shift for clinicians in the Middle East and North Africa. The decision to prescribe a DOAC for a patient with cancer is not always straightforward, particularly in challenging subgroups of patients with an increased risk of bleeding. In patients with gastrointestinal malignancies who are at high risk of major gastrointestinal bleeds, apixaban may be the preferred DOAC; however, caution should be exercised if patients have upper or unresected lower gastrointestinal tumors. In patients with gastrointestinal malignancies and upper or unresected lower gastrointestinal tumors, LMWH may be preferred. Vitamin K antagonists should be used only when DOACs and LMWH are unavailable or unsuitable. In this review, we discuss the overall evidence for DOACs in the treatment of cancer-associated VTE and provide treatment suggestions for challenging subgroups of patients with cancer associated VTE.
Collapse
Affiliation(s)
- Shouki Bazarbashi
- Section of Medical Oncology, Oncology Center, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia
| | - Heba Mohamed El Zawahry
- Department of Medical Oncology, The National Cancer Institute, Cairo University, Cairo, Egypt
| | - Tarek Owaidah
- Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center, Alfaisal University, Riyadh, Saudi Arabia
| | | | - Ashraf Warsi
- Department of Adult Hematology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs–Western Region, Jeddah, Saudi Arabia
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs–Western Region, Jeddah, Saudi Arabia
- King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs-Western Region, Jeddah, Saudi Arabia
| | - Mahmoud Marashi
- Hematology Department, Dubai Hospital, Dubai, United Arab Emirates
- Department of Hematology, Mediclinic City Hospital, Dubai, United Arab Emirates
| | - Emad Dawoud
- Department of Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Hassan Jaafar
- Department of Oncology, Sheikh Khalifa Specialty Hospital, Ras Al-Khaimah, United Arab Emirates
| | | | - Fady Haddad
- Vascular and Endovascular Surgery, American University of Beirut Medical Center, Beirut, Lebanon
| | - Alexander T Cohen
- Department of Haematological Medicine, Guy’s and St Thomas’ Hospitals NHS Foundation Trust, King’s College London, London, UK
| |
Collapse
|
2
|
Zoughbor SH, AlRasbi Z, Yousif A, Al Ameri M, Hussein MM, Hourani MS, Khamis SM, Ansari H, Syed I, Balaraj K, Azribi F, Bin Sumaida AR, Dawoud E, Ansari J. Unilateral Axillary Lymphadenopathy in Cancer Patients Post-COVID-19 Vaccination: Review and Case Series. Case Rep Oncol 2023; 16:188-203. [PMID: 37033700 PMCID: PMC10080460 DOI: 10.1159/000529913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 02/17/2023] [Indexed: 04/09/2023] Open
Abstract
Novel coronavirus-19 (COVID-19) variants continue to spread worldwide with the development of highly transmissible strains. Several guidelines addressing management of cancer patients during the COVID-19 pandemic have been published, primarily based upon expert opinion. The COVID-19 pandemic has affected all aspects of breast cancer care including screening, diagnosis, treatment, and long-term follow-up. Recent reports indicate that mRNA COVID-19 vaccines can provoke lymphadenopathy in both cancer patients and healthy individuals. Unilateral axillary lymphadenopathy (UAL) post-COVID-19 vaccination is a challenging presentation for cancer patients because of the potential for misinterpretation as malignancy. The World Health Organization’s target to vaccinate 70% of the world’s population by mid-2023 is likely to increase the incidence of post-COVID-19 vaccination UAL. In this article, we review the published evidence regarding UAL post-COVID-19 vaccination and present diverse cases of breast cancer patients where false-positive UAL post-COVID-19 vaccination proved to be a therapeutic challenge. The United Arab Emirates (UAE) vaccination program is well ahead of other countries in the world, having accomplished the target of 100% vaccination of the population with at least one dose. Therefore, an increasing number of recently vaccinated patients are likely to present with UAL, detected by surveillance imaging, post-vaccination. We have therefore made recommendations regarding the management of cancer patients with UAL post-COVID-19 vaccination in order to avoid misdiagnosis and unnecessary imaging or invasive biopsy procedures.
Collapse
Affiliation(s)
- Sumaya Hasan Zoughbor
- Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
- Zayed Center of Health Science, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
| | - Zakeya AlRasbi
- Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
- Zayed Center of Health Science, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE
| | - Ali Yousif
- Department of Oncology, Tawam Hospital, Al Ain, UAE
| | - Mouza Al Ameri
- Department of Breast Surgery, Tawam Hospital, Al Ain, UAE
| | | | | | | | - Hidayath Ansari
- Department of Nuclear Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE
| | | | | | - Fathi Azribi
- Department of Oncology, Tawam Hospital, Al Ain, UAE
| | | | - Emad Dawoud
- Department of Oncology, Tawam Hospital, Al Ain, UAE
| | | |
Collapse
|
3
|
Balalaa N, Anam W, Hussein M, Azribi F, Dawoud E, Trad D, Bennini N, Ansari J, Luiten E, Alawadhi A. Malignant Phyllodes tumor: A Multi-Tertiary Institutions retrospective analysis – United Arab Emirates (UAE) Experience. European Journal of Surgical Oncology 2023. [DOI: 10.1016/j.ejso.2022.11.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
|
4
|
Jazieh A, Sağlam EK, Önal H, Abdelkader Y, Gaafar R, Dawoud E, Nassar M, Alshorbagy D, El Ashry H, Alsayed M. Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa – KINDLE Study. Clin Lung Cancer 2022; 23:364-373. [DOI: 10.1016/j.cllc.2022.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 02/01/2022] [Accepted: 02/03/2022] [Indexed: 11/03/2022]
|
5
|
Ansari J, Eltigani Mohmmed Y, Ghazal-Aswad S, Ansari H, Akhter SMJ, Hassoun Hadid O, Rizwan S, Almazrouei R, Dawoud E, Azribi F, Elhasin H, Kumar P, Al Sumaida AR, Al-Qawasmeh K, Glaholm J, Hochmair MJ, Hussain S, Balaraj K. Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. Gynecol Oncol Rep 2021; 38:100878. [PMID: 34926759 PMCID: PMC8651786 DOI: 10.1016/j.gore.2021.100878] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Revised: 09/11/2021] [Accepted: 10/04/2021] [Indexed: 12/12/2022] Open
Abstract
Metastatic vaginal cancer, rare cancer with limited treatment options. Pembrolizumab and radiotherapy led to complete response in a patient with metastatic vaginal cancer. Wall-eyed bilateral internuclear ophthalmoplegia, a new immune related adverse event.
Primary vaginal cancer is a rare malignancy with a lack of international guidelines and supporting clinical trial evidence to guide decision making. Historical results have shown poor outcomes with chemotherapy for stage IVB vaginal squamous cell carcinoma (SCC). The evolving role of checkpoint inhibitors in rare gynaecological cancers prompted us to investigate the role of pembrolizumab in this setting. The efficacy of pembrolizumab in vaginal SCC has never been investigated in any clinical trial. There is established data to support the use of concurrent chemoradiotherapy in gynaecological cancers, however, the data for concurrent use of immunotherapy and radiotherapy is still lacking but is the subject of several clinical trials. We herein present the first reported case of chemotherapy refractory vaginal SCC with complete response to pembrolizumab and concurrent pelvic radiotherapy. We also present wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) as a rare but new immune related adverse event.
Collapse
Affiliation(s)
- Jawaher Ansari
- Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| | | | - Saad Ghazal-Aswad
- Department of Gynaecology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Hidayath Ansari
- Department of Radiology and Nuclear Medicine, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates
| | - Syed M J Akhter
- Department of Pathology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Omar Hassoun Hadid
- Department of Ophthalmology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Syed Rizwan
- Department of Radiology and Nuclear Medicine, Tawam Hospital, Al Ain, United Arab Emirates
| | - Raya Almazrouei
- Department of Endocrinology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Emad Dawoud
- Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Fathi Azribi
- Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Heba Elhasin
- Department of Neurology, Tawam Hospital, Al Ain, United Arab Emirates
| | - Pawan Kumar
- Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| | | | - Khaled Al-Qawasmeh
- Department of Medical Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| | - John Glaholm
- Institute of Cancer Research, London SM2 5NG, United Kingdom
| | - M J Hochmair
- Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord, 3500 Vienna, Austria
| | - Syed Hussain
- Department of oncology and metabolism, Room 228, 2nd Floor, Broomcross Building, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, United Kingdom
| | - Khalid Balaraj
- Department of Radiation Oncology, Tawam Hospital, Al Ain, United Arab Emirates
| |
Collapse
|
6
|
Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Al Sayed M, Burney I. Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study. BMC Cancer 2021; 21:1350. [PMID: 34930165 PMCID: PMC8690897 DOI: 10.1186/s12885-021-09094-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Accepted: 11/23/2021] [Indexed: 12/09/2022] Open
Abstract
BACKGROUND Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 PSVs is still not a routine practice in the Middle East. With the lack of epidemiological studies in the region, we aim to describe the prevalence of BRCA1/BRCA2 PSVs in patients with OC across different countries in the Gulf region. METHODS The PREDICT study was an observational, prospective, epidemiological study, which consecutively recruited women with ovarian, primary peritoneal, and fallopian tube cancers from the following Gulf countries over the period from July 2017 to July 2019; United Arab Emirates (UAE), Kuwait, and Oman. The study was approved by the local ethics committee of participating centers. The BRCA1/BRCA2 PSVs were assessed by tissue genetic testing using next-generation sequencing (NGS). RESULTS A total of 105 women were included with a median age at diagnosis of 52 years (IQR 44.5 - 61.0). Nearly 11.4% of patients reported a family history of ovarian or breast cancer, while 4.7% of patients reported a family history of other cancers. Most of the patients (70.3%) had advanced disease (FIGO stage III/IV) at presentation. Eighty-eight patients (84%) were successfully tested for somatic BRCA1/BRCA2 PSVs. Fifteen patients (17%) were found to have PSVs in either BRCA1, BRCA2, or both genes; of them, 10 patients (11.2%) had BRCA1 somatic PSVs alone, eight patients (9.1%) had BRCA2 somatic PSVs, while three patients (2.9%) had both PSVs. Five patients with BRCA1/BRCA2 somatic PSVs had germline PSVs tests, and three of them tested positive. Concerning treatment, 87.6% of patients received perioperative chemotherapy and 6.6% as first-line palliative chemotherapy. Eighty-seven (82.9%) patients underwent debulking surgery, with no residual disease in 42.5% of patients. CONCLUSION Our study showed that the prevalence of BRCA1/BRCA2 somatic PSVs in patients with OC is higher than the reported global figures (2-8%). However, more studies are warranted to further elucidate the prevalence of BRCA1/BRCA2 somatic and germline PSVs, as well as other relevant genetic alterations, to better understand their impact on OC patient outcomes in Gulf countries. TRIAL REGISTRATION NCT03082976 .
Collapse
Affiliation(s)
| | - Ehab Abdou
- Kuwait Cancer Control Center, Kuwait City, Kuwait
| | - Emad Dawoud
- Tawam Hospital, Al Ain, United Arab Emirates
| | | | - Amgad Kamal
- Medical Affairs Department, AstraZeneca, Dubai, United Arab Emirates
| | - Mohamed Al Sayed
- Medical Affairs Department, AstraZeneca, Dubai, United Arab Emirates
| | | |
Collapse
|
7
|
Jazieh A, Saglam EK, Önal H, Abdelkader Y, Gaafar R, Dawoud E, Nassar M, Alshorbagy D, El Ashry H, Alsayed M. 1177P Real-world treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Middle East and Africa (MEA)-KINDLE study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
8
|
Abdou E, Pedapenki RM, Abouagour M, Zar AR, Dawoud E, Elshourbagy D, Al-Shamsi HO, Grande E. Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. Expert Rev Anticancer Ther 2020; 20:831-840. [PMID: 32930617 DOI: 10.1080/14737140.2020.1810572] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
INTRODUCTION The approval of combination treatments for metastatic renal cell carcinoma (mRCC) represents a major change in the clinical management of this malignancy. Updated treatment guidelines differentiate first-line mRCC treatment by patient risk group as defined by prognostic models and the number of risk factors. AREAS COVERED Current prognostic models, with a focus on the International Metastatic RCC Database Consortium and the Memorial Sloan Kettering Cancer Center models, the heterogeneity of the intermediate risk group, and first- and second-line mRCC treatment outcomes according to patient risk group are discussed. Consideration is given to the future direction of treatment selection strategies including refinement of prognostic factors, genetic biomarkers and gene signatures. EXPERT OPINION Current prognostic models require updating, but initial data suggests they are effective in stratifying patients treated with immune checkpoint inhibitors or combination therapy. Treatment selection for patients with 1-2 risk factors may require further consideration due to the heterogeneous nature of the intermediate risk group. Future prognostic models may benefit from inclusion of gene signatures and stratification by molecular subtype. Prognostic risk factors are not the only consideration in treatment selection; tumor burden, location of metastases, and comorbidities, among other factors, should also be considered.
Collapse
Affiliation(s)
- Ehab Abdou
- Medical Oncology, Kuwait Cancer Control Center, Shuwaikh, Kuwait
| | | | | | - Abdul R Zar
- Department of Medical Oncology, National Center of Cancer Care and Research, Doha, Qatar
| | - Emad Dawoud
- Medical oncology, Tawam Hospital, Al Ain, UAE
| | | | - Humaid O Al-Shamsi
- College of Medicine, University of Sharjah, Sharjah, UAE.,Emirates Oncology Society, Dubai, UAE
| | - Enrique Grande
- Department of Medical Oncology, MD Anderson Cancer Center, Madrid, Spain
| |
Collapse
|
9
|
Azribi F, Abdou E, Dawoud E, Ashour M, Kamal A, Alsayed M, Burney I. 143P Prevalence of BRCA1/2 mutations in patients with ovarian cancer in the Gulf region: The PREDICT study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
10
|
Al-Shamsi H, Darr H, Abu-Gheida I, Ansari J, McManus MC, Jaafar H, Tirmazy SH, Elkhoury M, Azribi F, Jelovac D, Doufan TA, Labban AR, Basha AA, Samir A, Maarraoui A, Al Dameh A, Al-Awadhi A, Al Haj Ali B, Aboud B, Elshorbagy D, Trad D, Abdul Jabbar D, Hamza D, Ashtar E, Dawoud E, Aleassa EM, Khan F, Iqbal F, Abdellatif H, Afrit M, Masri MH, Abuhaleeqa M, Alfalasi M, Omara M, Diab M, Latif MF, Oner M, Dreier N, Almarzouqi O, Singarachari RA, Bendardaf R, Alrawi S, Aldeen SS, Rana S, Talima S, Abdelgawad T, Ahluwalia A, Alkasab T, Madi T, Alkhouri T, Ul Haq U, Alabed YZ, Azzam M, Ali Z, Abbas MA, Razek AA, Al-Khatib F. The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. Gulf J Oncolog 2020; 1:71-87. [PMID: 32342923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/02/2019] [Indexed: 06/11/2023]
Abstract
With cancer being the third leading cause of mortality in the United Arab Emirates (UAE), there has been significant investment from the government and private health care providers to enhance the quality of cancer care in the UAE. The UAE is a developing country with solid economic resources that can be utilized to improve cancer care across the country. There is limited data regarding the incidence, survival, and potential risk factors for cancer in the UAE. The UAE Oncology Task Force was established in 2019 by cancer care providers from across the UAE under the auspices of Emirates Oncology Society. In this paper we summarize the history of cancer care in the UAE, report the national cancer incidence, and outline current challenges and opportunities to enhance and standardize cancer care. We provide recommendations for policymakers and the UAE Oncology community for the delivery of high-quality cancer care. These recommendations are aligned with the UAE government's vision to reduce cancer mortality and provide high quality healthcare for its citizens.
Collapse
Affiliation(s)
- Humaid Al-Shamsi
- Emirates Oncology Society, Dubai, United Arab Emirates
- Department of Clinical Science, College of Medicine, University of Sharjah
| | - Humaa Darr
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Ibrahim Abu-Gheida
- Emirates Oncology Society, Dubai, United Arab Emirates
- Burjeel Medical City, Abu Dhabi, United Arab Emirates
| | - Jawaher Ansari
- Emirates Oncology Society, Dubai, United Arab Emirates
- Department of Oncology, Tawam Hospital, Al-Ain, United Arab Emirates
| | - Martine C McManus
- Emirates Oncology Society, Dubai, United Arab Emirates
- Burjeel Medical City, Abu Dhabi, United Arab Emirates
| | - Hassan Jaafar
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Sheikh Khalifa Speciality Hospital, Ras Al-Khaimah, United Arab Emirates
| | - Syed Hammad Tirmazy
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Dubai Hospital, Dubai, United Arab Emirates
| | - Maroun Elkhoury
- Emirates Oncology Society, Dubai, United Arab Emirates
- American Hospital, Dubai , United Arab Emirates
| | - Fathi Azribi
- Emirates Oncology Society, Dubai, United Arab Emirates
- Department of Oncology, Tawam Hospital, Al-Ain, United Arab Emirates
| | - Danijela Jelovac
- Department of Oncology, Tawam Hospital, Al-Ain, United Arab Emirates
- Breast Cancer Program, The Joh Hopkins Sydney Kimmel Comprehensive Cancer Center Baltimore, MD, USA
| | - Tarik A Doufan
- Emirates Oncology Society, Dubai, United Arab Emirates
- American Hospital, Dubai , United Arab Emirates
| | - Abdel Rahman Labban
- Emirates Oncology Society, Dubai, United Arab Emirates
- Advanced Care Oncology Center, Dubai , United Arab Emirates
| | - Ahmad Ali Basha
- Emirates Oncology Society, Dubai, United Arab Emirates
- Saudi German Hospital Dubai , Dubai, United Arab Emirates
| | - Ahmed Samir
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Aladdin Maarraoui
- Emirates Oncology Society, Dubai, United Arab Emirates
- Gulf International Cancer Center, Abu Dhabi, United Arab Emirates
| | - Ali Al Dameh
- Emirates Oncology Society, Dubai, United Arab Emirates
- American Hospital, Dubai , United Arab Emirates
| | - Aydah Al-Awadhi
- Emirates Oncology Society, Dubai, United Arab Emirates
- Department of Oncology, Tawam Hospital, Al-Ain, United Arab Emirates
| | - Basel Al Haj Ali
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Sheikh Khalifa Speciality Hospital, Ras Al-Khaimah, United Arab Emirates
| | - Batool Aboud
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Sheikh Khalifa Speciality Hospital, Ras Al-Khaimah, United Arab Emirates
| | - Dalia Elshorbagy
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Dubai Hospital, Dubai, United Arab Emirates
| | - Diaa Trad
- Emirates Oncology Society, Dubai, United Arab Emirates
- Department of Oncology, Tawam Hospital, Al-Ain, United Arab Emirates
| | - Dima Abdul Jabbar
- Emirates Oncology Society, Dubai, United Arab Emirates
- American Hospital, Dubai , United Arab Emirates
| | - Dina Hamza
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Dubai Hospital, Dubai, United Arab Emirates
| | - Ed Ashtar
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Emad Dawoud
- Emirates Oncology Society, Dubai, United Arab Emirates
- Department of Oncology, Tawam Hospital, Al-Ain, United Arab Emirates
| | - Essa M Aleassa
- Department of Surgery, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
- Section of Hepatopancreatobiliary Surgery, Department of Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic Foundation, Cleveland, OH, United States of America
| | - Faraz Khan
- Emirates Oncology Society, Dubai, United Arab Emirates
- American Hospital, Dubai , United Arab Emirates
| | - Faryal Iqbal
- Burjeel Medical City, Abu Dhabi, United Arab Emirates
| | - Hala Abdellatif
- Mediclinic Al Noor Hospital, Abu Dhabi, United Arab Emirates
| | - Mehdi Afrit
- Mediclinic Al Noor Hospital, Abu Dhabi, United Arab Emirates
| | - Mohamad H Masri
- Cleveland Clinic Abu Dhabi , Abu Dhabi , United Arab Emirates
| | | | - Mohamed Alfalasi
- Department of Surgery, Tawam Hospital, Al-Ain, United Arab Emirates
| | - Mohamed Omara
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Dubai Hospital, Dubai, United Arab Emirates
| | - Mohanad Diab
- NMC Specialty Hospital, Abu Dhabi , United Arab Emirates
| | - Muhammad Farooq Latif
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Dubai Hospital, Dubai, United Arab Emirates
| | - Muharram Oner
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | | | - Omar Almarzouqi
- Department of Surgery, Rashid Hospital, Dubai, United Arab Emirates
| | | | - Riyad Bendardaf
- Department of Clinical Science, College of Medicine, University of Sharjah
| | - Sadir Alrawi
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Salman Sray Aldeen
- Emirates Oncology Society, Dubai, United Arab Emirates
- Oncology Department, Sheikh Khalifa Speciality Hospital, Ras Al-Khaimah, United Arab Emirates
| | - Shabeeha Rana
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Soha Talima
- Zulekha Hospital Dubai, Dubai, United Arab Emirates
| | - Tamer Abdelgawad
- Emirates Oncology Society, Dubai, United Arab Emirates
- Advanced Care Oncology Center, Dubai , United Arab Emirates
| | - Abhinav Ahluwalia
- Emirates Oncology Society, Dubai, United Arab Emirates
- Advanced Care Oncology Center, Dubai , United Arab Emirates
| | - Thamir Alkasab
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Tamer Madi
- Emirates Oncology Society, Dubai, United Arab Emirates
- Alzahra Hospital, Dubai, United Arab Emirates
| | - Tarek Alkhouri
- Emirates Oncology Society, Dubai, United Arab Emirates
- Zulekha Hospital Dubai, Dubai, United Arab Emirates
| | - Urfan Ul Haq
- Burjeel Hospital, Abu Dhabi, United Arab Emirates
| | - Yazan Z Alabed
- Gulf International Cancer Center, Abu Dhabi, United Arab Emirates
| | - Mohamad Azzam
- Mediclinic Airport Road Cancer Center, Abu Dhabi, United Arab Emirates
| | - Zulfaqqar Ali
- Alzahra Hospital NMC , Shajah , United Arab Emirates
| | | | - Aly Abdel Razek
- Emirates Oncology Society, Dubai, United Arab Emirates
- Gulf International Cancer Center, Abu Dhabi, United Arab Emirates
| | | |
Collapse
|
11
|
Martens H, Dawoud E, Verachtert H. SYNTHESIS OF AROMA COMPOUNDS BY WORT ENTEROBACTERIA DURING THE FIRST STAGE OF LAMBIC FERMENTATION. Journal of the Institute of Brewing 2013. [DOI: 10.1002/j.2050-0416.1992.tb01126.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
12
|
Martens H, Dawoud E, Verachtert H. WORT ENTEROBACTERIA AND OTHER MICROBIAL POPULATIONS INVOLVED DURING THE FIRST MONTH OF LAMBIC FERMENTATION. Journal of the Institute of Brewing 2013. [DOI: 10.1002/j.2050-0416.1991.tb01082.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
13
|
Rashad F, Abd El-Nasser N, Dawoud E, Motawe F. TAXONOMICAL STUDIES ON ACTIVE Streptomyces ISOLATES FROM EGYPTIAN SOIL. Egyptian Journal of Agricultural Sciences 2009; 60:315-328. [DOI: 10.21608/ejarc.2009.215869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|